Table 1.
Demographic characteristic and treatment histories of 17 patients with stage IV uveal melanoma.
| ID | Gender | Age | Tumor volume in liver (%) | Largest tumor in liver (cm) | Extra-hepatic metastasis | Previous treatment liver-directed | Previous treatment others |
|---|---|---|---|---|---|---|---|
| 1 | F | 58 | 20–50 | 1.7 | None | Immunoembolization, radiosphere, TACE with BCNU | Ipi |
| 2 | M | 79 | < 20 | 2.2 | None | None | None |
| 3 | F | 77 | < 20 | 2.3 | Bone | Radiosphere, immunoembolization, TACE with BCNU | None |
| 4 | M | 68 | 20–50 | 3.2 | Bone, periportal LN, lung | Immunoembolization, TACE with BCNU | Carbo + Taxol, Xgeva, Ipi |
| 5 | F | 68 | < 20 | 3.4 | Lung, bone | Immunoembolization | MET Ab + MEKi, Ipi |
| 6 | M | 46 | < 20 | 3.5 | None | Immunoembolization | Adjuvant Sutent |
| 7 | M | 64 | < 20 | 3.9 | None | None | Adjuvant Sutent, METi |
| 8 | F | 35 | < 20 | 4.4 | Breast, pancreas, mediastinal LN, bone | Immunoembolization | Gemcitabine + Abraxane, VPA, MEKi, Cryoablation of pelvic metastasis |
| 9 | F | 78 | < 20 | 4.5 | Spine, skin | Immunoembolization, XRT to liver tumor, TACE with BCNU | None |
| 10 | F | 66 | < 20 | 4.6 | None | None | MEKi + AKTi, Ipi |
| 11 | F | 53 | < 20 | 4.7 | Bone, peritoneum, lung | Immunoembolization, TACE with BCNU | MET Ab, Ipi, VPA, PD-1 Ab |
| 12 | M | 63 | 20–50 | 6.9 | None | TACE with BCNU, DEBDOX | None |
| 13 | F | 50 | 20–50 | 7.4 | None | TACE with BCNU, DEBDOX | None |
| 14 | M | 36 | 20–50 | 8.2 | None | None | None |
| 15 | F | 40 | > 50 | 10.4 | None | TACE with BCNU, DEBDOX | Ipi |
| 16 | F | 58 | > 50 | 13.1 | None | TACE with BCNU | None |
| 17 | M | 71 | 20–50 | 14.3 | Muscle, brain, bone, peritoneum, skin | TACE with BCNU, DEBDOX | XRT to brain |
Note: Patients were sorted according to the size of the largest hepatic metastasis. Immunoembolization, embolization with granulocyte macrophage colony-stimulating factor plus Interleukin-2.